Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report

J Thorac Oncol. 2024 Apr;19(4):650-652. doi: 10.1016/j.jtho.2024.01.001. Epub 2024 Feb 9.


Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.

Keywords: Adjuvant; Case report; NSCLC; Osimertinib; Resistance.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides*
  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors / genetics
  • Humans
  • Indoles*
  • Lung Neoplasms* / drug therapy
  • Mutation
  • Protein Kinase Inhibitors
  • Pyrimidines*
  • Recurrence


  • osimertinib
  • ErbB Receptors
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • Acrylamides
  • Indoles
  • Pyrimidines